Last November, Nuritas, the Irish biotechnology company, closed a massive $45 million funding round to help accelerate its global expansion. The round brought the company’s total funding to $75 million and was a statement of confidence from a host of big-name backers including Chicago-based Cleveland Avenue, Grosvenor’s Wheatsheaf Group, and the European Circular Bioeconomy Fund (ECBF). Existing investors such as Bono, Adam Clayton and The Edge as well as Cultivian Sandbox Ventures also participated. The capital injection has shored up the company’s financial position, as evidenced by accounts filed by Nuritas in recent days for the 2021 financial year. When…

Want to read the full story?

Unlock this article – and everything else on The Currency – with an annual membership and receive a free Samsonite Upscape suitcase, retailing at €235, delivered to your door.

Subscribe

Cancel at any time.

Are you already a member? .